



Contact: Joel Huizenga
Location: La Jolla, California
Email: jhuizenga@ischemcorp.com
Tel: (858) 459-0011
Website: www.ischemcorp.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Medical Diagnostics

Company Overview:

ISCHEM non invasively identifies and concurrently localizes vulnerable plaque automatically (and hard plaque as well)

ISCHEM allows for the optimization of therapy and the monitoring of results for this threatening cardiovascular problem before it unexpectedly kills or debilitates.

Target Market(s): Heart disease and Stroke

Key Value Drivers

Technology*: The ability to noninvasively detect vulnerable plaque, the cause of heart disease and stroke.

Competitive Advantage: ISCHEM is the only company that has the ability to automatically and non-invasively detect vulnerable plaque in individuals. ISCHEM also an issued patent to protect this ability.

Plan & Strategy:

Co-Market and Co-Sales of the product with partners who already have a sales force in place in the territory for the customers that we are targeting.

Co-Deliver the product with the existing 3 Tesla MRI centers. Purchasing new centers when existing MRI centers are too full to accept new patients with the financial backing of the Three, 3 Tesla MRI, manufacturers.

Management

Leadership:

Joel Huizenga CEO
Beatrice Golomb, MD, PhD Executive VP, Medical Director
Michael Willoughby, PhD CFO
Tom Brotherton, PhD CTO
Russell Anderson, VP of Development

Scientific Advisory Board:

Antonio M. Gotto, Jr., M.D. Cornell University
Bradford C. Berk, M.D., Ph.D. University of Rochester
Valentin Fuster, M.D., Ph.D. Sinai Medical School, NY, NY
David P. Faxon, M.D. Harvard University
Justin A. Zivin, M.D., Ph.D. University of California, San Diego
Halbert White, Ph.D. University of California, San Diego
David Zipser, Ph.D. University of California, San Diego (Emeritus)
Robert F. Labbé, Ph.D. University of Washington (Emeritus)

Product Pipeline

Two Medical Prognostic / Diagnostic products for the:

- 1) ACUTE PREVENTION OF HEART ATTACK AND STROKE***
- 2) LONGER TERM PREVENTION OF HEART ATTACK AND STROKE***